Nuvig Therapeutics Secures $161M Funding for Phase 2 Study in Autoimmune Diseases

Funding:
Nuvig Therapeutics has raised $161 million to support its Phase 2 study for treating autoimmune diseases3.

Lead Molecule:
The company's lead molecule, NVG-2089, is a manufactured antibody fragment that mimics the action of intravenous immunoglobulin (IVIg) but with improved efficacy and reduced dosing requirements1 2.

Disease Focus:
NVG-2089 is initially being tested for Chronic Idiopathic Demyelinating Polyneuropathy (CIDP), a condition that leads to gradual loss of walking ability and numbness in extremities2.

Synthetic Manufacturing:
Nuvig's use of synthetic manufacturing eliminates the need for costly blood donations, addressing supply shortages and rationing issues associated with IVIg1.

Future Plans:
The company plans to test NVG-2089 in one or two different dermatological autoimmune disorders where IVIG use is validated2.

Mission:
Nuvig Therapeutics aims to bring innovative and transformational therapies to patients with chronic autoimmune diseases by inducing mechanisms that restore immune homeostasis4 5.